Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Egyptian International Pharmaceutical Investments's quarterly Other Stockholders Equity
stayed the same
from Jun. 2025 (E£3,113 Mil) to Sep. 2025 (E£3,113 Mil) but then
declined
from Sep. 2025 (E£3,113 Mil) to Mar. 2026 (E£2,778 Mil).
Egyptian International Pharmaceutical Investments's annual Other Stockholders Equity
increased
from Dec. 2022 (E£1,531 Mil) to Dec. 2023 (E£1,870 Mil) and
increased
from Dec. 2023 (E£1,870 Mil) to Dec. 2024 (E£1,957 Mil).
Egyptian International Pharmaceutical Investments Other Stockholders Equity Related Terms
Egyptian International Pharmaceutical Investments Other Stockholders Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments Other Stockholders Equity Chart
Egyptian International Pharmaceutical Investments Annual Data
What does a Other Stockholders Equity of E£2,778 Mil mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Other Stockholders Equity of E£2,778 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Egyptian International Pharmaceutical Investments and its competitors.
Is Egyptian International Pharmaceutical Investments' Other Stockholders Equity too high?
Egyptian International Pharmaceutical Investments' current Other Stockholders Equity is E£2,778 Mil. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Other Stockholders Equity compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' Other Stockholders Equity of E£2,778 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current Other Stockholders Equity is E£2,778 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.92, compared to a current price of E£90.10 — trading 50.4% above its estimated fair value. The current Other Stockholders Equity is E£2,778 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 73/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Other Stockholders Equity is E£2,778 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£90.10 is trading 50.4% above its estimated GF Value™ of E£59.92.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
Other Stockholders Equity: E£2,778 Mil
GF Value™: E£59.92 vs. price of E£90.10 (50.4% above fair value)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
73GF Score
Get the complete analysis for CAI:PHAR
Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
